由瘤疗法引起的心脏毒性和可能的免疫反应中的miRNA调节
1Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur, 303002, India.
Current medicinal chemistry
|September 8, 2025
概括
抗癌疗法可能会导致心脏问题 (心脏毒性),增加癌症患者的死亡率. 微RNAs (miRNAs) 是关键的调节者,为药物诱导的心脏毒性提供了早期检测和新型治疗的潜力.
科学领域:
- 心脏病学 心脏病学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 抗癌疗法存在重大心血管风险,包括高血压和心律失常,导致癌症患者的死亡率.
- 药物诱导的心脏毒性是一个主要问题,需要更好的理解和管理策略.
研究的目的:
- 探索癌症治疗中心脏毒性的调节机制.
- 研究微RNAs (miRNAs) 在药物诱导心脏毒性的作用.
- 为了确定潜在的诊断和治疗策略,针对miRNA来管理心脏毒性.
主要方法:
- 审查心脏毒性的调节机制,包括氧化应激,线粒体损伤,亡和炎症.
- 分析微RNAs (miRNAs) 在遗传,表观遗传,转录和转化调节心脏毒性的作用.
- 探索针对miRNAs的新型诊断和治疗方法.
主要成果:
- 微RNAs (miRNAs) 在调节药物诱导心脏毒性的各种过程中发挥着至关重要的作用.
- 在早期检测心脏毒性方面,MiRNAs显示出作为生物标志物的潜力.
- 向miRNAs为新型治疗干预提供了一个有希望的途径.
结论:
- 了解miRNA介导调节对于管理癌症患者心脏毒性至关重要.
- 基于MiRNA的诊断和治疗方法可以显著改善临床结果.
- 对miRNA作用的进一步研究可以导致更安全,更有效的抗癌治疗.
相关概念视频
MicroRNAs
3.8K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.8K
MicroRNAs
23.9K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.9K
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Cytotoxic T Cells-mediated Immune Response
6.5K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.5K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K


